"uuid:ID","name","text","identifier","label","id","description","instanceType"
"9260fd9b-05e4-4e83-a592-2ae50ef6d603","Age Criteria","Subjects shall be between [min_age] and [max_age]","1","","EligibilityCriterion_1","The study age criterion","EligibilityCriterion"
"30910fbb-7b2d-40e4-b832-af339ec19f98","Pop Criteria","[StudyPopulation] as defined by the NINCDS and the ADRDA guidelines (Attachment LZZT.7)","2","","EligibilityCriterion_2","The study population criterion","EligibilityCriterion"
"a37edb11-c3fe-4514-b324-fe2428529bcf","Diag Criteria","[Activity1] score of 10 to 23","3","","EligibilityCriterion_3","The study diagnosis criterion","EligibilityCriterion"
"13d76828-9240-44e0-ac90-322edb294c2a","Previous Criteria","Persons who have previously completed or withdrawn from this study or any other study investigating xanomeline TTS or the oral formulation of xanomeline.","9","","EligibilityCriterion_4","The previous xanomeline TTS criterion","EligibilityCriterion"
